Today Raymond James Reaffirms a Outperform Rating on Regenxbio (RGNX) and a $96 Target Price

September 8, 2018 - By Carolyn Hewitt

REGENXBIO Inc. (NASDAQ:RGNX) Logo

Regenxbio (RGNX) Rating Reaffirmed

They currently have a $96 target price per share on Regenxbio (RGNX). The target price by Raymond James would suggest a potential upside of 29.82 % from the company’s last stock close price. This has been disclosed to clients in a note on 7 September.

REGENXBIO Inc. (NASDAQ:RGNX) Ratings Coverage

Among 7 analysts covering Regenxbio (RGNX), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Regenxbio has $130 highest and $2900 lowest target. $76.43’s average target is 3.35% above currents $73.95 stock price. Regenxbio had 10 analyst reports since March 12, 2018 according to SRatingsIntel. The stock of REGENXBIO Inc. (NASDAQ:RGNX) earned “Outperform” rating by Raymond James on Friday, September 7. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, March 14. As per Monday, March 12, the company rating was downgraded by Evercore. The stock of REGENXBIO Inc. (NASDAQ:RGNX) earned “Overweight” rating by Barclays Capital on Monday, August 13. The firm has “Buy” rating given on Monday, April 9 by Chardan Capital Markets. Chardan Capital Markets maintained the shares of RGNX in report on Monday, July 16 with “Buy” rating. Chardan Capital Markets maintained the shares of RGNX in report on Tuesday, July 10 with “Buy” rating. The stock of REGENXBIO Inc. (NASDAQ:RGNX) has “Hold” rating given on Wednesday, May 9 by Mizuho. Bank of America downgraded it to “Neutral” rating and $80 target in Monday, July 23 report. Morgan Stanley maintained the shares of RGNX in report on Friday, July 13 with “Overweight” rating.

The stock increased 0.07% or $0.05 during the last trading session, reaching $73.95. About 258,052 shares traded. REGENXBIO Inc. (RGNX) has risen 165.15% since September 8, 2017 and is uptrending. It has outperformed by 152.58% the S&P500.

Analysts await REGENXBIO Inc. (NASDAQ:RGNX) to report earnings on November, 14. They expect $-0.91 EPS, down 35.82 % or $0.24 from last year’s $-0.67 per share. After $0.15 actual EPS reported by REGENXBIO Inc. for the previous quarter, Wall Street now forecasts -706.67 % negative EPS growth.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $2.62 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It has a 31.26 P/E ratio. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

More news for REGENXBIO Inc. (NASDAQ:RGNX) were recently published by: Nasdaq.com, which released: “New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic …” on August 27, 2018. Seekingalpha.com‘s article titled: “REGENXBIO up 8% on new pipeline candidate for Batten disease” and published on August 30, 2018 is yet another important article.

REGENXBIO Inc. (NASDAQ:RGNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.